Results 171 to 180 of about 80,718 (256)

Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing tn antigen. [PDF]

open access: yesJ Biol Chem, 2012
Mi R   +12 more
europepmc   +1 more source

A global survey of blood transfusion practices for patients with sickle cell disease

open access: yesTransfusion, EarlyView.
Abstract Background Sickle cell disease (SCD) affects over 7 million people globally, with blood transfusion remaining a cornerstone of management. However, contemporary transfusion practices across diverse settings remain poorly characterized. We evaluated global transfusion practices for patients with SCD to identify gaps and inform resource ...
Jeremy W. Jacobs   +18 more
wiley   +1 more source

Analysis of ADVIA Myeloperoxidase Cytogram LUC Angle Does Not Distinguish Acute Myeloid Leukemia From Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma in Dogs

open access: yesVeterinary Clinical Pathology, EarlyView.
ABSTRACT Background Acute myeloid leukemia (AML) is difficult to distinguish from lymphoblastic leukemia or lymphoma (LL) on morphologic features alone. Therapeutic approaches for AML versus LL differ, and immediate therapy is often needed due to patient illness and rapid disease progression.
Mayzie Miller   +4 more
wiley   +1 more source

Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium

open access: yesInternational Journal of Cancer, Volume 159, Issue 6, Page 1477-1489, 15 September 2026.
In recent years, incorporating comprehensive cancer screening strategies into routine HIV care has gained growing attention. This survey of 220 sites providing HIV care across 41 countries shows that cervical cancer screening has increased in availability over time.
Rachael A. Pellegrino   +32 more
wiley   +1 more source

A cancer therapeutic vaccine based on clustered Tn-antigen mimetics induces strong antibody-mediated protective immunity. [PDF]

open access: yesAngew Chem Int Ed Engl, 2014
Richichi B   +7 more
europepmc   +1 more source

Clinical Predictors of Response in Chronic Graft‐Versus‐Host Disease: Results From the “Predicting the Quality of Response to Specific Treatments (PQRST)” Trial

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2280-2287, September 2026.
ABSTRACT Despite significant progress in chronic GVHD therapies, challenges remain in understanding pleomorphic phenotypes and varying responses to treatment. The aim of this study was to identify predictors of treatment response. We conducted a prospective, observational cohort study of patients beginning first‐, second‐, or third‐line systemic ...
Betty K. Hamilton   +11 more
wiley   +1 more source

Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody. [PDF]

open access: yesAngew Chem Int Ed Engl, 2015
Martínez-Sáez N   +14 more
europepmc   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

open access: yesMedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source

G3BP1 Succinylation at K413 is Critical for Cardiac Function by Modulating PI3K‐AKT‐mTOR Signal Axis

open access: yesAdvanced Science, Volume 13, Issue 43, 3 August 2026.
Schematic illustrating the impact of G3BP1 succinylation at K413 on cardiac function. In the healthy human heart, G3BP1 succinylation maintains homeostatic mTOR signaling. In patients with dilated cardiomyopathy (DCM) and heart failure (HF), G3BP1 de‐succinylation induces RagA expression and disrupts the binding of the TSC1/2 complex, leading to the ...
Yuan Zhang   +9 more
wiley   +1 more source

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis

open access: yesAmerican Journal of Hematology, Volume 101, Issue 8, Page 1928-1937, August 2026.
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and ...
Murali Janakiram   +94 more
wiley   +1 more source

Home - About - Disclaimer - Privacy